CRISPR Therapeutics AG (CRSP) Total Liabilities (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Total Liabilities of $911.3 million for Q1 2026, up 165.34% sequentially from $343.4 million in Q4 2025, and up 170.45% YoY from $336.9 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Total Liabilities (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Total Liabilities for 12 years, with the latest figure at $911.3 million in Q1 2026.
- Quarterly Total Liabilities rose 170.45% year-over-year to $911.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $911.3 million (up 170.45% YoY) and the FY2025 annual result came in at $343.4 million, up 10.8% from the prior year.
- Total Liabilities improved to $911.3 million in Q1 2026 per CRSP's latest filing, from $343.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $911.3 million in Q1 2026 and troughed at $310.0 million in Q4 2024.
- A 5-year average of $385.7 million and a median of $358.9 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities decreased 11.86% in 2024, then jumped 170.45% in 2026.
- Over 5 years, Total Liabilities stood at $367.6 million in 2022, then retreated by 5.66% to $346.8 million in 2023, then decreased by 10.62% to $310.0 million in 2024, then increased by 10.8% to $343.4 million in 2025, then surged by 165.34% to $911.3 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $911.3 million, $343.4 million, and $329.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 904.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 904.22 Mn |
| Mar 31, 2026 | 911.26 Mn |
| Dec 31, 2025 | 343.43 Mn |
| Sep 30, 2025 | 329.33 Mn |
| Jun 30, 2025 | 318.59 Mn |
| Mar 31, 2025 | 336.94 Mn |
| Dec 31, 2024 | 309.95 Mn |
| Sep 30, 2024 | 316.47 Mn |
| Jun 30, 2024 | 358.90 Mn |
| Mar 31, 2024 | 355.08 Mn |
| Dec 31, 2023 | 346.77 Mn |
| Sep 30, 2023 | 359.04 Mn |
| Jun 30, 2023 | 380.99 Mn |
| Mar 31, 2023 | 389.47 Mn |
| Dec 31, 2022 | 367.58 Mn |
| Sep 30, 2022 | 399.40 Mn |
| Jun 30, 2022 | 372.53 Mn |
| Mar 31, 2022 | 361.26 Mn |
| Dec 31, 2021 | 352.42 Mn |
| Sep 30, 2021 | 308.80 Mn |